FRAMINGHAM, MA, October 30, 2007 - GTC Biotherapeutics, Inc. ("GTC", Nasdaq: GTCB) announced today that Geoffrey Cox, Ph.D., GTC's Chairman and CEO, is scheduled to present on Tuesday, November 6, 2007 at 2:20 p.m. during the Acumen BioFin Rodman & Renshaw 9th Annual Healthcare Conference. The conference is being held at the New York Palace Hotel in New York, New York from November 5 - 7, 2007.
The presentation will be webcast live and can be accessed by logging ontohttp://www.gtc-bio.com. The replay can be accessed from this same website and will be available within 24 hours of the presentation.
About GTC Biotherapeutics
GTC Biotherapeutics develops, produces, and commercializes therapeutic proteins through transgenic animal technology. GTC obtained the first approval anywhere in the world for a transgenically produced protein when ATrynŽ, a recombinant form of human antithrombin, was approved by the European Commission for use in patients with hereditary antithrombin deficiency undergoing surgical procedures. GTC's intellectual property includes a patent in the United States through 2021 for the production of any therapeutic protein in the milk of any transgenic mammal. GTC's transgenic production platform is particularly well suited to enabling cost effective development of proteins that are difficult to express in traditional recombinant production systems as well as those that are required in large volumes. Additional information is available on the GTC web site, http://www.gtc-bio.com.
CONTACT:
GTC Biotherapeutics, Inc.
Thomas E. Newberry
Vice President, Corporate Communications
(508) 370-5374 or tom.newberry@gtc-bio.com Feinstein Kean Healthcare for GTC
Francesca Nolan
(617) 577-8110 or francesca.nolan@fkhealth.com
Copyright 2007 GTC Biotherapeutics, All Rights Reserved